| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(10)70187-X |
| P698 | PubMed publication ID | 20739218 |
| P50 | author | Jesús San Miguel | Q5930658 |
| Ramón García-Sanz | Q37830539 | ||
| Norma C. Gutiérrez | Q39399978 | ||
| Albert Oriol | Q47344831 | ||
| María-Belén Vidriales | Q51533824 | ||
| Joaquin Martinez-Lopez | Q63688958 | ||
| Josep-Maria Ribera | Q80465686 | ||
| María Luisa Mateos-Martín | Q83990174 | ||
| Maria Teresa Cibeira | Q87885213 | ||
| Joan Bladé | Q87885218 | ||
| Bruno Paiva | Q88009013 | ||
| María Victoria Mateos | Q89582275 | ||
| Jose Luis Bueso Bello | Q91390234 | ||
| Enrique García Bengoechea | Q100724483 | ||
| Juan José Lahuerta | Q100736896 | ||
| Joan Bargay | Q114426347 | ||
| Joaquín Díaz-Mediavilla | Q117261608 | ||
| Ana Sureda | Q117261609 | ||
| Felipe de Arriba | Q117261611 | ||
| José García-Laraña | Q117261612 | ||
| Ana-Isabel Teruel | Q117261618 | ||
| María-Luisa Martín-Ramos | Q117261654 | ||
| María-Angeles Montalbán | Q117261662 | ||
| P2093 | author name string | Yolanda González | |
| Raquel de Paz | |||
| Luis Palomera | |||
| Alejandro Martín | |||
| Francisco-Javier Peñalver | |||
| Jose-Mariano Hernández | |||
| P2860 | cites work | Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial | Q28252396 |
| Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients | Q33680252 | ||
| Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials | Q34307206 | ||
| Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 | ||
| Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma | Q34815786 | ||
| Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities | Q36941047 | ||
| Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation | Q36969778 | ||
| Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone | Q37268930 | ||
| Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls | Q39361121 | ||
| Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study | Q43048164 | ||
| Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial | Q43109172 | ||
| Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone | Q43195076 | ||
| Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. | Q46006794 | ||
| Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. | Q46068547 | ||
| Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure | Q46094234 | ||
| Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. | Q46573449 | ||
| Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial | Q46985882 | ||
| Hazard Rate Models with Covariates | Q52776795 | ||
| Cox regression methods for two-stage randomization designs. | Q54532642 | ||
| Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated | Q60203798 | ||
| Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study | Q60203808 | ||
| Two-stage randomization designs in drug development | Q81499185 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 934-941 | |
| P577 | publication date | 2010-08-23 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial | |
| P478 | volume | 11 |
| Q42132657 | A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma |
| Q39836136 | A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells |
| Q40783660 | A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. |
| Q37373159 | A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma |
| Q33914056 | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma |
| Q36055752 | APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma |
| Q38248293 | Advances in multiple myeloma therapy during two past decades |
| Q38833538 | Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation |
| Q42716199 | Age and aging in blood disorders: multiple myeloma |
| Q30595175 | Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials |
| Q38685796 | Allogeneic stem cell transplantation for multiple myeloma: is there a future? |
| Q35923000 | Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report |
| Q90029028 | Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist |
| Q38122624 | Association of response endpoints with survival outcomes in multiple myeloma |
| Q37216380 | Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial. |
| Q38021041 | Bortezomib combination therapy in multiple myeloma |
| Q33696008 | Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy |
| Q93144918 | Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later |
| Q24185881 | Bortezomib for the treatment of multiple myeloma |
| Q33982728 | Bortezomib in multiple myeloma: systematic review and clinical considerations |
| Q35063100 | Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma |
| Q43794256 | Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study |
| Q90117531 | Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis |
| Q95326326 | Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study |
| Q33626064 | Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study |
| Q42929917 | Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma |
| Q36852225 | Challenges in multiple myeloma diagnosis and treatment |
| Q59329492 | Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project |
| Q60203477 | Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients |
| Q101133052 | Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma |
| Q37835572 | Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. |
| Q38249930 | Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques |
| Q47996009 | Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. |
| Q38087939 | Current approaches for the treatment of multiple myeloma |
| Q41819491 | Current approaches to the initial treatment of symptomatic multiple myeloma |
| Q38412189 | Current therapeutic strategies for multiple myeloma |
| Q38542091 | Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development |
| Q38789282 | Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials |
| Q36848078 | Design Issues in Randomized Clinical Trials of Maintenance Therapies |
| Q60697532 | Design and Analysis Considerations for Comparing Dynamic Treatment Regimens with Binary Outcomes from Sequential Multiple Assignment Randomized Trials |
| Q90469550 | Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma |
| Q38107482 | Diagnosis and therapy of multiple myeloma |
| Q38062037 | Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy? |
| Q45412209 | Early mortality in multiple myeloma |
| Q52668514 | Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. |
| Q36494358 | Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations |
| Q37362054 | Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study. |
| Q38095968 | Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma |
| Q38089497 | Efficacy of bortezomib as first-line treatment for patients with multiple myeloma |
| Q64074928 | Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis |
| Q90563372 | Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro |
| Q34585577 | Estimation of optimal dynamic treatment regimes |
| Q35989943 | European perspective on multiple myeloma treatment strategies: update following recent congresses |
| Q27026478 | Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies |
| Q33431175 | Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study |
| Q55119916 | Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. |
| Q60949296 | How I treat elderly patients with plasma cell dyscrasias |
| Q38062039 | How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events |
| Q38809499 | Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab |
| Q50118881 | Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT. |
| Q36595290 | Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. |
| Q33902726 | In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells |
| Q26991817 | Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis |
| Q38146974 | Incorporating novel agents in the management of elderly myeloma patients |
| Q30830842 | Inference about the expected performance of a data-driven dynamic treatment regime |
| Q46754093 | Integration of Novel Agents into the Care of Patients with Multiple Myeloma |
| Q35802414 | International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation |
| Q27002668 | International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation |
| Q83425696 | Is subcutaneous bortezomib ready for prime time? |
| Q35675837 | Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma |
| Q36525841 | Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients |
| Q39001325 | Management of Elderly Patients with Plasma Cell Myeloma |
| Q49989009 | Management of multiple myeloma in the newly diagnosed patient. |
| Q37970946 | Management of treatment-emergent peripheral neuropathy in multiple myeloma. |
| Q38605484 | Managing multiple myeloma in elderly patients |
| Q92276356 | Managing treatment-related peripheral neuropathy in patients with multiple myeloma |
| Q26852892 | Many multiple myelomas: making more of the molecular mayhem |
| Q35171777 | Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma |
| Q36051084 | Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma |
| Q36290238 | Molecular pathogenesis of multiple myeloma and its premalignant precursor |
| Q27026205 | Molecular pathogenesis of multiple myeloma: basic and clinical updates |
| Q89582276 | Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients |
| Q55119496 | Multiple Myeloma: Diagnosis and Treatment. |
| Q100316249 | Multiple myeloma current treatment algorithms |
| Q34031129 | Multiple myeloma in the older adult: better prospects, more challenges |
| Q26752991 | Multiple myeloma in the very elderly patient: challenges and solutions |
| Q37858327 | Multiple myeloma treatment strategies with novel agents in 2011: a European perspective |
| Q36777233 | Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management |
| Q37623809 | Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management |
| Q58565204 | Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management |
| Q36470699 | Myeloma today: Disease definitions and treatment advances |
| Q64901832 | Navigating the treatment landscape in multiple myeloma: which combinations to use and when? |
| Q38048281 | New Treatment Approaches for Older Adults with Multiple Myeloma |
| Q38191867 | New approaches to management of multiple myeloma. |
| Q51761449 | Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults? |
| Q38261677 | Novel agents and new therapeutic approaches for treatment of multiple myeloma. |
| Q37995195 | Novel treatment paradigm for elderly patients with multiple myeloma |
| Q38796491 | Nuances in the Management of Older People With Multiple Myeloma |
| Q30370038 | Older patients with myeloma derive similar benefit from autologous transplantation. |
| Q54970050 | Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy. |
| Q28077567 | Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice |
| Q44386061 | Optimizing multiple myeloma treatment: conclusions |
| Q41543966 | Outcomes of primary refractory multiple myeloma and the impact of novel therapies |
| Q85350362 | Panobinostat for the treatment of multiple myeloma |
| Q56385082 | Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) |
| Q41602673 | Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations |
| Q35266125 | Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 |
| Q33415759 | Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma |
| Q37274353 | Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma |
| Q33406992 | Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma |
| Q37275721 | Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients |
| Q37970604 | Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis |
| Q64078554 | Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature |
| Q48682753 | Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. |
| Q33621587 | Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma |
| Q38014395 | Proteasome inhibitors in multiple myeloma: 10 years later |
| Q58712153 | Real-World Clinical Outcomes in Elderly Chinese Patients with Multiple Myeloma: A Single-Center Experience |
| Q82303516 | Reduced-intensity induction therapy for elderly patients with multiple myeloma |
| Q35607162 | SMART designs in cancer research: Past, present, and future |
| Q52637974 | Safety and comfort of domestic bortezomib injection in real-life experience. |
| Q41849927 | Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma |
| Q39576312 | Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited |
| Q36851424 | Senior adult oncology |
| Q39027826 | Sequencing of nontransplant treatments in multiple myeloma patients with active disease |
| Q92836682 | Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma |
| Q87870251 | Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma |
| Q36893299 | Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy |
| Q38232055 | Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits |
| Q48686917 | Subcutaneous bortezomib: a step towards optimised drug use. |
| Q38075800 | Subcutaneous bortezomib: in multiple myeloma |
| Q33400871 | Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone |
| Q85516007 | Sustained disease control in transplant-ineligible patients: the role of continuous therapy |
| Q36251560 | Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy |
| Q36382493 | Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study |
| Q26795764 | The 26S proteasome is a multifaceted target for anti-cancer therapies |
| Q64107988 | The Challenges of Informed Consent in High-Stakes, Randomized Oncology Trials: A Systematic Review |
| Q37644252 | The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma |
| Q28539605 | The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma |
| Q38163937 | The effects of bortezomib on bone disease in patients with multiple myeloma |
| Q33917164 | The future of autologous stem cell transplantation in myeloma |
| Q38246060 | The future of proteasome inhibitors in relapsed/refractory multiple myeloma. |
| Q36706899 | The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution |
| Q64967112 | The pharmacologic management of multiple myeloma in older adults. |
| Q36612613 | The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development |
| Q38375463 | The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents |
| Q38252583 | Therapeutic advancements in multiple myeloma |
| Q30538040 | Time-dependent endpoints as predictors of overall survival in multiple myeloma |
| Q38815405 | Treatment of Newly Diagnosed Elderly Multiple Myeloma. |
| Q83975326 | Treatment of multiple myeloma |
| Q37846567 | Treatment of newly diagnosed myeloma in patients not eligible for transplantation. |
| Q39035350 | Treatment of newly diagnosed myeloma: Bortezomib-based triplet |
| Q37949201 | Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. |
| Q38311072 | Tretatment approach of nontransplant patients with multiple myeloma |
| Q28082910 | Trial Watch: Proteasomal inhibitors for anticancer therapy |
| Q37946701 | Update on risk stratification and treatment of newly diagnosed multiple myeloma. |
| Q33440007 | Update on the optimal use of bortezomib in the treatment of multiple myeloma |
| Q35905929 | Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib |
| Q36936514 | Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma |
| Q42123569 | Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients |
| Q91692405 | Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data |
| Q35244911 | Waldenstrom macroglobulinemia: prognosis and management |
| Q90527991 | [First-line treatment of multiple myeloma] |
Search more.